Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Biophysical Characterization of the Tandem FHA Domain Regulatory Module from the Mycobacteriumtuberculosis ABC Transporter Rv1747.

Heinkel F, Shen L, Richard-Greenblatt M, Okon M, Bui JM, Gee CL, Gay LM, Alber T, Av-Gay Y, Gsponer J, McIntosh LP.

Structure. 2018 May 17. pii: S0969-2126(18)30164-3. doi: 10.1016/j.str.2018.04.018. [Epub ahead of print]

PMID:
29861345
2.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW.

Clin Cancer Res. 2018 Apr 3. doi: 10.1158/1078-0432.CCR-18-0373. [Epub ahead of print]

PMID:
29615459
3.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM.

Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

PMID:
29540602
4.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

5.

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Sun J, Miller VA, Stephens PJ, Gay LM.

Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.

6.

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21. No abstract available.

PMID:
29325860
7.

Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.

Lin DI, Chudnovsky Y, Duggan B, Zajchowski D, Greenbowe J, Ross JS, Gay LM, Ali SM, Elvin JA.

Gynecol Oncol. 2017 Dec;147(3):626-633. doi: 10.1016/j.ygyno.2017.09.031. Epub 2017 Nov 6.

PMID:
29102090
8.

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.

Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM.

Oncologist. 2017 Dec;22(12):1444-1450. doi: 10.1634/theoncologist.2016-0488. Epub 2017 Oct 27.

PMID:
29079636
9.

General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.

Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS.

Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24.

PMID:
29079173
10.

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.

Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, Somerset H, Johnson JM, Russell J, Ali S, Schrock AB, Fabrizio D, Frampton G, Miller V, Stephens PJ, Elvin JA, Bowles DW.

Ann Oncol. 2017 Oct 1;28(10):2539-2546. doi: 10.1093/annonc/mdx399.

PMID:
28961851
11.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

PMID:
28945887
12.

Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer.

Morse CB, Elvin JA, Gay LM, Liao JB.

Gynecol Oncol Rep. 2017 Jun 27;21:78-80. doi: 10.1016/j.gore.2017.06.013. eCollection 2017 Aug.

13.

BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.

Mayor P, Gay LM, Lele S, Elvin JA.

Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.

14.

Structure and function of a broad-specificity chitin deacetylase from Aspergillus nidulans FGSC A4.

Liu Z, Gay LM, Tuveng TR, Agger JW, Westereng B, Mathiesen G, Horn SJ, Vaaje-Kolstad G, van Aalten DMF, Eijsink VGH.

Sci Rep. 2017 May 11;7(1):1746. doi: 10.1038/s41598-017-02043-1.

15.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.

Gay LM, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C, Battiste J, Colon-Otero G, Powell S, Russell J, Elvin JA, Vergilio JA, Suh J, Ali SM, Stephens PJ, Miller VA, Ross JS.

Oncologist. 2017 Jul;22(7):834-842. doi: 10.1634/theoncologist.2016-0287. Epub 2017 May 11.

PMID:
28495808
16.

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options.

Elvin JA, Chura J, Gay LM, Markman M.

Gynecol Oncol Rep. 2017 Mar 1;20:62-66. doi: 10.1016/j.gore.2017.02.007. eCollection 2017 May.

17.

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

Elvin JA, Gay LM, Ort R, Shuluk J, Long J, Shelley L, Lee R, Chalmers ZR, Frampton GM, Ali SM, Schrock AB, Miller VA, Stephens PJ, Ross JS, Frank R.

Oncologist. 2017 Apr;22(4):416-421. doi: 10.1634/theoncologist.2016-0310. Epub 2017 Mar 10.

18.

Comprehensive genomic profiling of malignant phyllodes tumors of the breast.

Nozad S, Sheehan CE, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon S, Schrock AB, Hirshfield KM, Ali N, Ganesan S, Ali SM, Miller VA, Stephens PJ, Ross JS, Chung JH.

Breast Cancer Res Treat. 2017 Apr;162(3):597-602. doi: 10.1007/s10549-017-4156-1. Epub 2017 Feb 17.

PMID:
28210881
19.

Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.

Carlson JA, Caldeira Xavier JC Jr, Tarasen A, Sheehan CE, Otto G, Miller VA, Stephens PJ, Elvin JA, Vergilio JA, Suh J, Gay LM, Ross JS.

Am J Dermatopathol. 2017 Jan;39(1):1-13. doi: 10.1097/DAD.0000000000000729.

PMID:
28045747
20.

Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.

Ross JS, Gay LM.

Pathology. 2017 Feb;49(2):120-132. doi: 10.1016/j.pathol.2016.11.005. Epub 2016 Dec 26.

PMID:
28034454
21.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

22.

Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.

Ross JS, Gay LM, Nozad S, Wang K, Ali SM, Boguniewicz A, Khaira D, Johnson A, Elvin JA, Vergilio JA, Suh J, Miller VA, Stephens PJ.

Breast Cancer Res Treat. 2016 Jan;155(2):405-13. doi: 10.1007/s10549-016-3682-6. Epub 2016 Jan 13.

PMID:
26762307
23.

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib.

Chung JH, Ali SM, Davis J, Robstad K, McNally R, Gay LM, Erlich RL, Palma NA, Stephens PJ, Miller VA, Cutugno A, Ross JS.

Case Rep Oncol. 2014 Sep 9;7(3):628-32. doi: 10.1159/000367780. eCollection 2014 Sep.

24.

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.

Ross JS, Wang K, Gay LM, Al-Rohil RN, Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, Palmer G, Ali S, Nahas M, Young G, Labrecque E, Frampton G, Erlich R, Curran JA, Brennan K, Downing SR, Yelensky R, Lipson D, Hawryluk M, Miller VA, Stephens PJ.

Clin Cancer Res. 2014 Jan 1;20(1):68-75. doi: 10.1158/1078-0432.CCR-13-1992. Epub 2013 Nov 5.

25.

Molecular recognition: O-GlcNAc transfer: size matters.

Gay LM, Zheng X, van Aalten DM.

Nat Chem Biol. 2011 Mar;7(3):134-5. doi: 10.1038/nchembio.529. No abstract available.

26.
27.

Structure/function studies of Ser/Thr and Tyr protein phosphorylation in Mycobacterium tuberculosis.

Greenstein AE, Grundner C, Echols N, Gay LM, Lombana TN, Miecskowski CA, Pullen KE, Sung PY, Alber T.

J Mol Microbiol Biotechnol. 2005;9(3-4):167-81. Review.

PMID:
16415590
28.
29.

Recombination signature of germline immunoglobulin variable genes.

Weiller GF, Rothenfluh HS, Zylstra P, Gay LM, Averdunk H, Steele EJ, Blanden RV.

Immunol Cell Biol. 1998 Apr;76(2):179-85.

PMID:
9619489

Supplemental Content

Support Center